Behind Allergan’s Developments after 2Q17
A look at Allergan
Headquartered in Dublin, Ireland, Allergan (AGN) is a leading pharmaceutical company focused on developing, manufacturing, and commercialization of pharmaceuticals, devices, and biologic products worldwide.
Interested in AGN? Don't miss the next report.
Receive e-mail alerts for new research on AGN
AGN’s recent developments
On September 19, 2017, Allergan’s Allure received three 2017 Best of the Beauty Breakthrough awards. The three products that were awarded include Juvederm Volbella XC, SkinMedica Lytera 2.0 Pigment Correction Serum, and Rhofade Cream 1%.
On September 12, 2017, Allergan launched the next generation of US-based Brilliant Distinctions program. The new program includes a new digital platform, and additional products like CoolSculpting, an aesthetic portfolio from Allergan, Botox Cosmetic and Juvederm, SkinMedica products, and Latisse, from the facial aesthetics portfolio.
On September 8, 2017, Allergan and Saint Regis Mohawk Tribe announced that the Orange Book-listed patents for Restasis are owned by Tribe, while Allergan holds the licenses to these patents related to Restasis.
On September 6, 2017, Allergan announced that the company will release new data on chronic migraine at the International Headache Congress 2017 in Vancouver. On August 28, 2017, Allergan announced the settlement its patent litigation with FamyCare for Restasis 0.05%. These patents are listed in the Orange Book and are valid up to August 27, 2024.
On July 27, 2017, Allergan’s drug Truberzi (eluxadoline) received a positive recommendation from NICE (National Institute of Health and Care Excellence) for the treatment of adults with irritable bowel syndrome with diarrhea. Truberzi is a twice-daily oral medication for the treatment of bloating, diarrhea, pain, and urgency in patients with irritable bowel syndrome with diarrhea.